PROTECT PHARMACEUTICAL Corp: 10-Q filed 2013-11-19
What PROTECT PHARMACEUTICAL Corp reported in its quarterly report filed 2013-11-19 (fiscal Q3 2013): 14 published measures, 36 facts as tagged in accession 0001551163-13-000189.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2013-11-19
- Fiscal period
- fiscal Q3 2013
- Accession
- 0001551163-13-000189 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PROTECT PHARMACEUTICAL Corp filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 726 | USD | |
| At 2012-12-31 | 860 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 593,376 | USD | |
| At 2012-12-31 | 578,049 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | -592,650 | USD | |
| At 2012-12-31 | -577,189 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 726 | USD | |
| At 2012-12-31 | 860 | USD | |
| At 2012-09-30 | 905 | USD | |
| At 2011-12-31 | 22,171 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | -5,558 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -19,961 | USD | 273 |
| 1987-08-05 to 2013-09-30 | -12,890,705 | USD | 9554 |
| 2012-07-01 to 2012-09-30 | -123,117 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -545,963 | USD | 274 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | -134 | USD | 273 |
| 1987-08-05 to 2013-09-30 | -506,927 | USD | 9554 |
| 2012-01-01 to 2012-09-30 | -22,217 | USD | 274 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 1987-08-05 to 2013-09-30 | -132,347 | USD | 9554 |
| 2012-01-01 to 2012-09-30 | 951 | USD | 274 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 1987-08-05 to 2013-09-30 | 640,000 | USD | 9554 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 726 | USD | |
| At 2012-12-31 | 860 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 593,376 | USD | |
| At 2012-12-31 | 578,049 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 1987-08-05 to 2013-09-30 | 1,353,540 | USD | 9554 |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 8,353,480 | USD | |
| At 2012-12-31 | 8,348,980 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | -19,961 | USD | 273 |
| 1987-08-05 to 2013-09-30 | -12,890,705 | USD | 9554 |
| 2012-01-01 to 2012-09-30 | -545,963 | USD | 274 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 45 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 135 | USD | 273 |
| 1987-08-05 to 2013-09-30 | 447,074 | USD | 9554 |
| 2012-07-01 to 2012-09-30 | 30 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 16,773 | USD | 274 |
Inspect the source
- Entity
- PROTECT PHARMACEUTICAL Corp / CIK 0001493526
- Captured
- SEC response SHA-256
bf1ce86f3a2d5eb5f9d9f7f0fbe211675520a0792f638ea498f1809d5f6f06c8
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001493526.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))